Objective To analyze the effect of complement C5a and related inflammatory factors on blood pressure and its role in hypertension in obese children,in order to provide scientific reference for clinical intervention. Methods A cross-sectional study was conducted from July 2016 to August 2017 among 71 obese children,recruited from the Second Affiliated Hospital of Xi′an Jiaotong University.Children′s height,weight,waist circumference,body mass index (BMI) and blood pressure were measured.According to the blood pressure measurement results,systolic blood pressure (SBP) and/or diastolic blood pressure(DBP)≥same age P95 as hypertension were further divided into hypertension group and non-hypertension group.Serum insulin,IL-6,C5a,hsCRP and TNF-α were detected by enzyme linked immunosorbent assay(ELISA).The insulin resistance index (HOMA-IR) was calculated and the test results were analyzed. Results The levels of HOMA-IR,triglyceride (TG),total cholesterol (TC),TNF-α,IL-6 and complement C5a in hypertensive children were significantly higher than those in non-hypertensive children (P<0.05).Pearson correlation analysis showed that both SDS-DBP and SDS-SBP were related to the levels of TNF-α,hsCRP,IL-6 and C5a(P<0.05).Multiple linear regression showed that SDS-BMI,waist circumference,IL-6,C5a and hsCRP were significantly correlated with SDS-SBP (P<0.05).Moreover,IL-6,C5a and hsCRP were significantly correlated with SDS-DBP. Conclusion IL-6,hsCRP and C5a play an important role in the development of hypertension in obese children,and may be the risk factors for hypertension
Key words
obese children /
hypertension /
inflammatory factors /
complement C5a
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Ogden CL,Carroll MD,Kit BK,et al.Prevalence of obesity and trends in body mass index among US children and adolescents,1999-2010[J].JAMA,2012,307(5):483-490.
[2] Babinska K,Kovacs L,Janko V,et al.Association between obesity and the severity of ambulatory hypertension in children and adolescents[J].J Am Soc Hypertens,2012,6(5):356-363.
[3] Vlachopoulos C,Gravos A,Georgiopoulos G,et al.The effect of TNF-α antagonists on aortic stiffness and wave reflections:a meta-analysis[J].Clin Rheumatol,2018,37(2):515-526.
[4] Haapakoski R,Mathieu J,Ebmeier KP,et al.Cumulative meta-analysis of interleukins 6 and 1β,tumour necrosis factor α and C-reactive protein in patients with major depressive disorder[J].Brain Behav Immun,2015,49:206-215
[5] Sahebkar A,Serban C,Ursoniu S,et al.Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-Results from a systematic review and meta-analysis of randomized controlled trials[J].Int J Cardiol,2015,189:47-55.
[6] Laine P,Pentikainen MO,Wurzner R,et al.Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction[J].Am J Cardiol, 2012,90(4):404-408.
[7] 米杰.我国高血压的防治必须从儿童抓起[J].中华预防医学杂志,2014,48(5):337-339.
[8] Caillon A,Schiffrin EL.Role of inflammation and immunity in hypertension:recent epidemiological,laboratory,and clinical evidence[J].Curr Hypertens Rep,2016,18(3):21.
[9] Qian YS,Tang XF,Zhang J,et al.C-reactive protein (CRP) gene polymorphisms,CRP levels and risk of incident essential hypertension:findings from an observational cohort of Han Chinese[J].Hypertens Res,2012,35(10):1019-1023.
[10] Hage FG.C-reactive protein and hypertension[J].J Hum Hypertens,2014,28(7):410.
[11] Yao Y,Chang W,Jin Y.Association between TNF-a promoter-308G/A polymorphism and essential hypertension in the Asian population:a meta-analysis[J].J Renin Angiotensin Aldosterone Syst,2017,18(4):1-6.
[12] Vidal F,Fontes TV,Marques TV F,et al.Association between apical periodontitis lesions and plasmatic levels of C-reactive protein,interleukin 6 and fibrinogen in hypertensive patients[J].Int Endod J,2016,49(12):1107-1115.
[13] Chen J,Han L,Xu X,et al.Serum biomarkers VEGF-C and IL-6 are associated with severe human peripheral artery stenosis[J].J Inflamm,2015,12(1):50.
[14] Jasiewicz M,Knapp M,Waszkiewicz E,et al.Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage[J].Cytokine,2015,76(2):187-192.
[15] Wenzel UO,Bode M,Khl J,et al.A pathogenic role of complement in arterial hypertension and hypertensive end organ damage[J].Am J Physiol Heart Circ Physiol,2017,312(3):H349-H354.
[16] Ruan CC,Ma Y,Ge Q,et al.Complement-mediated inhibition of adiponectin regulates perivascular inflammation and vascular injury in hypertension[J].FASEB J,2017,31(3):1120-1129.
[17] Iyer A,Woodruff TM,Wu MC L,et al.Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats[J].J Cardiovasc Pharmacol,2015,58(5):479-486.
PDF(544 KB)
